TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02023112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267
Study: NCT03435666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELODA
Description: Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
Study: NCT03681054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restricted diet
Description: The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-protein based diet
Description: The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 50 E%; fat 30 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
Study: NCT02283242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Oral use for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for galantamine)
Description: Oral use for 12 weeks
Study: NCT02023112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule
Study: NCT03488238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORi sensor
Description: Noninvasive pulse oximeter sensor that is placed on the finger for measurement of ORi
Study: NCT00755872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
Study: NCT03154307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency repeated TMS (LF-rTMS)
Description: Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency repeated TMS (LF-rTMS)
Description: Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low frequency repeated TMS (LF-rTMS)
Description: Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency repeated TMS (LF-rTMS)
Description: Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
Study: NCT01549457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell phone text messages
Description: Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
Study: NCT03094819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retinal Care DR
Description: Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
Study: NCT01438307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel-XRP6258 (3-week cycle)
Description: Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel-XRP6258 (5-week cycle)
Description: Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
Study: NCT03657810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108 5 mg
Description: hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco
Description: hydrocodone 5 mg/APAP 325 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching CL-108
Study: NCT00669032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: 3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
Study: NCT01360229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture to treat fatigue in Parkinson disease
Description: Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
Study: NCT01345370

Intervention type: DRUG
Intervention: Temozolomide
Description: According to sites procedures

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: According to sites procedures
Study: NCT01241656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESI for home viewing
Description: Decision support intervention is a 31 minute DVD mailed to the patients in all of the experimental groups. The program explains the function and location of the prostate and the nature of prostate cancer, including its associated mortality. Next, the program describes the different tests that are used to detect prostate cancer including the digital rectal exam, prostate specific antigen (PSA) test and prostate biopsy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESI for viewing at Shared Medical Appointment
Description: Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Option of SMA and DESI or DESI only
Description: Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
Study: NCT01998399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Study: NCT04077164

Intervention type: OTHER
Intervention: No intervention, observational only.
Description: No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.

Intervention type: OTHER
Intervention: No intervention, observational only.
Description: No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.
Study: NCT04127669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSU 6162
Description: The active ingredient of OSU6162 is the S-enantiomer with the chemical name (S)-3-\[3-(methylsulfonyl)phenyl\]-1-propylpiperidine hydrochloride. The substance is a white powder with a melting point of 177-182°C. Solubility in water is \> 2000 mg/ml. Current laboratory code used is OSU6162-HCl. In trial protocol, OSU6162-HCl is shortened to OSU6162.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Circular coated tablet (with identical appearance to active treatment tablets 15 mg).
Study: NCT01216722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Strengthening Exercise Program
Description: Home exercise Program. 3-4 days a week. 30 minutes a session. 12 weeks
Study: NCT01463020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone delivered BA
Description: A 8 week behavioural activation therapy delivered through smartphone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone delivered mindfulness
Description: A 8 week mindfulness intervention delivered through smartphone
Study: NCT04429321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg IV every four weeks, first in combination with capecitabine then alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, in combination with Nivolumab

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bland embolization
Description: Lipiodol:ethanol embolization of their primary or target tumor
Study: NCT03588611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: 0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: 0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: 0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: 0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
Study: NCT03990259

Intervention type: OTHER
Intervention: Running the CSP Mountain Race
Description: The runners completed a 107,6 km mountain race

Intervention type: OTHER
Intervention: Running the CSP Mountain Race
Description: The runners completed a 107,6 km mountain race
Study: NCT03205982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wise app with medication adherence reminders
Description: The Intervention group will receive the Wise app that delivers medication adherence reminders.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wise app with fitness reminders
Description: The control group will receive the Wise app with fitness reminders
Study: NCT01254578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03990090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02352103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retzius sparing radical prostatectomy
Description: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vattikuti Urology Institute radical prostatectomy
Description: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: da Vinci Surgical System
Description: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci Surgical System
Description: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
Study: NCT01495923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural steroid injection
Description: Injection of steroids and local anesthetic into the epidural space

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham epidural steroid injection
Description: Injection of saline into the back muscles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Titration of gabapentin to effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo gabapentin
Description: Titration of placebo gabapentin
Study: NCT02460978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for dapagliflozin
Description: Tablets
Study: NCT01261598

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Positron Emission Tomography
Description: Positron Emission Tomography

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Positron Emission Tomography
Description: Positron Emission Tomography
Study: NCT02141217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanate
Description: Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
Study: NCT04254055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Those subjects included in the experimental group will receive an intervention through a program with plyometric, proprioceptive and strength exercises. The subjects included in the control group will not receive any intervention.
Study: NCT04239170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab(SHR-1210)
Description: Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin
Study: NCT01619605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shrimp challenge
Description: Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
Study: NCT02307318

Intervention type: DEVICE
Group type: OTHER
Intervention: SoftSeal Hemostatic Pad
Description: Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
Study: NCT00661570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provox Vega voice prosthesis (20 Fr)
Description: The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
Study: NCT01176188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort Care
Description: The intervention will consist of two parts: (1) A 15-20 minute period of parental soothing at the bedside comprised of calming activities which the child and parents are familiar with; (2) A quiet period will follow, in which earmuffs are applied over the child's ears to block auditory stimulation. The intervention will take place twice/24 hours, up to a maximum of 72 hours. Total time of first (daytime) intervention will be 2 hours, and of second (night-time) intervention will be 7 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual nursing care for the child in the Pediatric Intensive Care Unit, including usual parental involvement and usual exposure to unit noise levels.
Study: NCT00655057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-citalopram
Description: Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRODAT-1 single photon emission computed tomographic (SPECT) imaging
Description: Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRODAT-1 single photon emission computed tomographic (SPECT) imaging
Description: Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRODAT-1 single photon emission computed tomographic (SPECT) imaging
Description: Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.